Women's Health: Worldwide Prescription Drug Markets
1. Get more info on this report!
Women's Health: Worldwide Prescription Drug Markets
February 1, 2009
Women’s health encompasses all different areas of medicine and it would be a
monumental task to address all of the areas that affect women. This report will
concentrate on disorders that affect the female reproductive system and other disorders
where there is at least a 70% preponderance of women affected by the disorder. The
worldwide prescription drug market for women’s health consists of total manufacturers’
revenues from the following product categories:
• Autoimmune diseases
• Cancer
• Gynecological and Sexually Transmitted Diseases
• Hormones
• Osteoporosis
• Urinary Disorders
Women's Health: Worldwide Prescription Drug Markets, represents the fourth time that
Kalorama Information has tackled the women's health pharmaceutical market.
Revenues from these segments are not reported in total, as certain segments affect
both men and women. The analysis and market data in this report estimate revenues
associated with therapeutics for women only. Segmentation within each category is by
major drug type and by geographic region (U.S., Europe, Japan, ROW). All market data
pertain to the U.S. market at the manufacturers’ level. Data are expressed in current
U.S. dollars. The base year for data was 2007. forecast data are provided for each of
the years 2009 through 2013. Historical, base year, and forecast data are provided for
each market segment. Market shares are provided for each market segment for the
2007 base year.
In addition to market data, the report contains extensive product pipeline information,
competitor profiles, and discussions of the major industry issues and trends shaping the
market.
The information and analysis presented in this report are based on an extensive survey
of senior management in the prescription women’s health drug industry. Background
2. information was obtained from a comprehensive search of published literature and
reports obtained from various government, business, medical trade, and international
journals. Key information from published literature was used to conduct interviews with
over 40 industry executives and product managers to validate and obtain expert opinion
on current and future trends in the women’s health industry. Interviews were also used
to confirm and/or adjust market size and market share estimates, as well as in
formulating market projections.
Table of Contents
CHAPTER ONE:EXECUTIVE SUMMARY
• Scope and Methodology
• Size and Growth of the Market
• Total Market Size and Forecast
• Market Outlook
CHAPTER TWO: INTRODUCTION AND OVERVIEW
• History of Women’s Health
• Female Reproductive System
• Hormone Regulation
• Market Trends
o Women’s Health Initiative
o Women’s Health Office Act of 2007
o Perimenopausal Use of Contraceptives
o Insurance Coverage for Contraceptives
o Oral Contraceptives in Japan
o Ovarian Cancer Test
o Estrogen Labeling
o Osteoporosis Drug Opportunities in Asia
o Women’s Healthcare Access
• Demographics
CHAPTER THREE: AUTOIMMUNE DISEASES
• Overview
• Prevalence
• Chronic Fatigue Syndrome
• Treatment
• Fibromyalgia
• Treatment
• Rheumatoid Arthritis
• Treatment
• Scleroderma
• Treatment
3. • Sjogren’s Syndrome
• Treatment
• Systemic Lupus Erythematosus
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
o Ampligen
o Actemra
o Apilimod
o Arcoxia
o Cimza
o Denosumab
o INCBO18424
o Interleukin (IL-1)
o LymphoStat-B
o Milnacipran
o Prestara
o Riquent
o Veldona
• Competitive Market
CHAPTER FOUR: CANCER
• Overview
• Incidence and Mortality
• Breast Cancer
• Overview
• Treatment
• Cervical Cancer
• Overview
• Treatment
• Endometrial Cancer
• Overview
• Treatment
• Ovarian Cance
• Overview
• Treatment
• Vaginal Cancer
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Advexin
• Alvespimycin
4. • Arzoxifene
• Avastin
• Axtinib
• Cervarix
• Herceptin
• Karenitecin
• Pazopanib
• Pertuzumab
• Tykerb
• Yondeli
• Competitive Market
CHAPTER FIVE: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED
DISEASES
• Overview
• Incidence and Prevalence
• AIDS
o Overview
o Treatment
o Agenerase
o Aptivus
o Combivir
o Crixivan
o Entriva
o Fortovase
o Fuzeon
o Hivid
o Intelence
o Invirase
o Isentress
o Kaletra
o Kivexa
o Lexiva
o Prezista
o Rescriptor
o Reyataz
o Selzentry
o Sustiva
o Trizivir
o Truvada
o Viracept
o Viramune
• Bacterial Vaginosis
• Overview
• Treatment
5. • Cervical Dysplasia
• Overview
• Treatment
• Chlamydia
• Overview
• Treatment
• Condyloma Acuminata
• Overview
• Treatment
• Aldara
• Alferon N Injection
• Condylox
• Gardasil
• Genital Herpes
• Overview
• Treatment
• Zovirax
• Gonorrhea
• Overview
• Treatment
• Hepatitis
• Overview
• Treatment
• Baraclude
• Pelvic Inflammatory Disease
• Overview
• Treatment
• Syphilis
• Overview
• Treatment
• Toxic Shock Syndrome
• Overview
• Treatment
• Yeast Infections
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
o Ampligen
o Bevirimat
o Boceprevir
o Clevudine
o Elvitegravir
o GS 9137
o Hepaconda
6. o IC41
o IDX899
o Loctero
o R7128
o RDEA806
o SPO1A
o Telaprevir
o TMC278
o Vicriviroc
o VRX496
• Competitive Market
CHAPTER SIX: HORMONE-RELATED DISORDERS
• Overview
• Statistics
• Contraception
• Overview
• Treatment
• Oral Contraceptives
• Depo-Provera
• Birth Control Patch
• Vaginal Ring
• Emergency Contraception and Early Option
• Implant
• IUD
• Endometriosis
• Overview
• Treatment
• Fibroids
• Overview
• Treatment
• Infertility
• Overview
• Treatment
• Menopause
• Overview
• Treatment
• Menstrual Disorders
• Amenorrhea
• Treatment
• Dysmenorrhea
• Treatment
• Sexual Dysfunction
• Overview
• Treatment
7. • Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Alista
• LibiGel
• NOMAC/E2
• Ophena
• Org 36286
• Competitive Market
CHAPTER SEVEN: OSTEOPOROSIS
• Overview
• Prevalence
• Prevention
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Arzoxifene
• Denosumab
• Fablyn
• MK-0822 (Odanacatib)
• Preos
• SUN E3001
• Viviant
• Competitive Market
CHAPTER EIGHT: URINARY BLADDER DISORDERS
• Overview
• Incidence and Prevalence
• Cystitis
• Overview
• Treatment
• Incontinence
• Overview
• Treatment
• Overactive Bladder
• Treatment
• Alternative Treatments
• Interstitial Cystitis
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
8. • Research and Development
• Oxybutynin Gel
• Anturol
• PSD503
• Competitive Market
CHAPTER NINE: WORLD MARKET SUMMARY
• Overview
• Total Market Size and Forecast
• Market Analysis
CHAPTER TEN:CORPORATE PROFILES AND ANALYSIS
• Overview
APPENDIX: COMPANY DIRECTORY: MAJOR SUPPLIERS
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
• Table 1-1: The World Market Women’s Disorders 2006-2013
• Figure 1-1: The World Market Women’s Disorders 2006-2013
CHAPTER TWO: INTRODUCTION AND OVERVIEW
• Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2007
• Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries,
2007 (Difference, in Years, between Females and Males)
• Table 2-2: World Population Growth, by Total World Population and Selected
Country or Regions and Selected Characteristics
• Figure 2-2: World Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in
millions)
• Figure 2-3: United States Population Growth by Sex 2000, 2005, 2010, 2020,
2025 (in millions)
• Figure 2-4: Five Major European Countries* Population Growth by Sex 2000,
2005, 2010, 2020, 2025 (in millions)
• Figure 2-5: Japan Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in
millions)
• Table 2-3: World Female Population Growth by Selected Country or Regions and
Selected Age Group
• Figure 2-6: World Female Population Growth by Selected Age Group 2000,
2005, 2010, 2020, 2025 (in millions)
• Figure 2-7: United States Female Population Growth by Selected Age Group
2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-8: Five Major European Countries* Female Population Growth by
Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
9. • Figure 2-9: Japan Female Population Growth by Selected Age Group 2000,
2005, 2010, 2020, 2025 (in millions)
CHAPTER THREE: AUTOIMMUNE DISEASES
• Table 3-1: Estimated Female Prevalence of Autoimmune Diseases by Type and
Geographical Distribution, Estimated 2008
• Table 3-2: The World Market for Autoimmune Disease Drugs for Women 2006-
2013
• Figure 3-1: The World Market for Autoimmune Disease Drugs for Women 2006-
2013
• Table 3-3: The World Market for Autoimmune Disease Drugs for Women by
Disease Type 2006-2013
• Figure 3-4: The World Market for Autoimmune Disease Drugs for
• Table 3-4 Women, Revenues by Disease Type 2006-2013
• Figure 3-3: The World Market for Autoimmune Disease Drugs for
• Figure 3-4: The World Market for Autoimmune Disease Drugs for Women,
Market Share by Disease Type 2013
• Table 3-8: The World Market for Autoimmune Disease Drugs for
• Women Market Analysis by Region/Country, 2008
• Figure 3-5: The World Market for Autoimmune Disease Drugs for Women Market
Analysis by Region/Country, 2008
• Table 3-5 Select Products in Development for Chronic Fatigue Syndrome 2008
• Table 3-6: Select Products in Development for Fibromyalgia 2008
• Table 3-7: Select Products in Development for Rheumatoid Arthritis 2008
• Table 3-8: Products in Development for Sjogren’s Syndrome, 2008
• Table 3-9: Products in Development for Systemic Lupus Erythematosus 2008
• Table 3-6: The World Market for Autoimmune Disease Drugs for Women
Revenues and Market Share by Supplier 2008
• Figure 3-10: The World Market for Autoimmune Disease Drugs for Women
Market Share by Leading Supplier 2008
CHAPTER FOUR: CANCER
• Table 4-1: Estimated Incidence of Female Cancers and Mortality by Type and
Geographical Distribution, Estimated 2008
• Table 4-2: The World Market for Cancer Drugs for Women 2006-2013
• Figure 4-1: The World Market for Cancer Drugs for Women 2006-2013
• Table 4-3: The World Market for Cancer Drugs for Women by Disease Type
2006-2013
• Figure 4-2: The World Market for Cancer Drugs for Women, Revenues by
Cancer Type 2006-2013
• Figure 4-3: The World Market for Cancer Drugs for Women, Market Share by
Cancer Type 2008
• Figure 4-4: The World Market for Cancer Drugs for Women, Market Share by
Cancer Type 2013
10. • Table 4-4: The World Market for Cancer Drugs for Women Market Analysis by
Region/Country, 2008
• Figure 4-5: The World Market for Cancer Drugs for Women Market Analysis by
Region/Country, 2008
• Table 4-5: Select Products in Development for Breast Cancer 2008
• Table 4-6: Select Products in Development for Cervical Cancer 2008
• Table 4-7: Select Products in Development for Endometrial Cancer 2008
• Table 4-8: Select Products in Development for Ovarian Cancer 2008
• Table 4-9: Select Products in Development for Vaginal Cancer, 2008
• Table 4-6: The World Market for Cancer Drugs for Women Revenues and Market
Share by Supplier 2008
• Figure 4-10: The World Market for Cancer Drugs for Women Market Share by
Leading Supplier 2008
CHAPTER FIVE: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED
DISEASES
• Table 5-1: Estimated Female Incidence and Prevalence Gynecological and
Sexually Transmitted Diseases by Type and Geographical Distribution,
2007/2008
• Table 5-2: Gynecological and Sexually Transmitted Diseases Related
Epidemiologic Data, Five Year Average 2007/2008 Average
• Table 5-3: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women 2006-2013
• Figure 5-1: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women 2006-2013
• Table 5-4: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women by Disease Type 2006-2013
• Figure 5-2: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women, Revenues by Disease Type 2006-2013
• Figure 5-3: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women, Market Share by Disease Type 2008
• Figure 5-4: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women, Market Share by Disease Type 2013
• Table 5-5: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women Market Analysis by Region/Country, 2008
• Figure 5-5: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women Market Analysis by Region/Country, 2008
• Table 5-6: Select Products in Development for AIDS/HIV 2008
• Table 5-7: Select Products in Development for Cervical Dysplagia 2008
• Table 5-8: Select Products in Development for Condyloma Acumenta 2008
• Table 5-9: Select Products in Development for Genital Herpes 2008
• Table 5-10: Select Products in Development for Hepatitis, 2008
• Table 5-6: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women Revenues and Market Share by Supplier 2008
11. • Figure 5-11: The World Market for Gynecological Infections and Sexually
Transmitted Diseases for Women Market Share by Leading Supplier 2008
CHAPTER SIX: HORMONE-RELATED DISORDERS
• Table 6-1: Estimated World and U.S. Female Incidence and Prevalence of
Hormone-Related Disorders and Indications by Type, Five Year Average
2007/2008
• Table 6-2: Estimated World and U.S. Contraceptive Use by Method, Five Year
Average 2007/2008
• Table 6-3: Selected Oral Contraceptives Available 2007/2008
• Table 6-4: Selected Hormone Replacement Therapies
• Table 6-5: The World Market for Hormone-related Disorders for Women, 2006-
2013
• Figure 6-1: The World Market for Hormone-related Disorders for Women 2006-
2013
• Table 6-6: The World Market for Hormone-related Disorders for Women by
Disorder Type 2006-2013
• Figure 6-2: The World Market for Hormone-related Disorders for Women,
Revenues by Disorder Type 2006-2013
• Figure 6-3: The World Market for Hormone-related Disorders for Women, Market
Share by Disorder Type 2008
• Figure 6-4: The World Market for Hormone-related Disorders for Women, Market
Share by Disorder Type 2013
• Table 6-7: The World Market for Hormone-related Disorders for Women Market
Analysis by Region/Country, 2008
• Figure 6-5: The World Market for Hormone-related Disorders for Women Market
Analysis by Region/Country, 2008
• Table 6-8: Select Products in Development for Oral Contraceptives 2008
• Table 6-9: Select Products in Development for Endometriosis 2008
• Table 6-10: Select Products in Development for Infertility 2008
• Table 6-11: Select Products in Development for Menopause 2008
• Table 6-12: Select Products in Development for Menstrual Disorders 2008
• Table 6-13: Select Products in Development for Sexual Dysfunction 2008
• Table 6-14: The World Market for Hormone-related Disorders for Women
Revenues and Market Share by Supplier 2008
• Figure 6-6: The World Market for Hormone-related Disorders for Women Market
Share by Leading Supplier 2008
CHAPTER SEVEN: OSTEOPOROSIS
• Table 7-1: Estimated Female Prevalence of Osteoporosis by Type and
Geographical Distribution, Average 2007/2008
• Table 7-2: The World Market for Osteoporosis Treatments for Women 2006-2013
• Figure 7-1: The World Market for Osteoporosis Treatments for Women 2006-
2013
12. • Table 7-3: The World Market for Osteoporosis Treatments for Women Market
Analysis by Region/Country, 2008
• Figure 7-2: The World Market for Osteoporosis Treatments for Women Market
Analysis by Region/Country, 2008
• Table 7-4: Select Products in Development for Osteoporosis Drugs 2008
• Table 7-5: The World Market for Osteoporosis Treatments for Women Revenues
and Market Share by Supplier 2008
• Figure 7-3: The World Market for Osteoporosis Treatments for Women Market
Share by Leading Supplier 2008
CHAPTER EIGHT: URINARY BLADDER DISORDERS
• Table 8-1: Estimated Female Incidence and Prevalence of Urinary Bladder
Disorders by Type and Geographical Distribution, Average 2007/2008
• Table 8-2: Medications That Can Affect Urination
• Table 8-3: The World Market for Urinary Bladder Disorders for Women 2006-
2013
• Figure 8-1: The World Market for Urinary Bladder Disorders for Women 2006-
2013
• Table 8-4: The World Market for Urinary Bladder Disorders for Women by
Disease Type 2006-2013
• Figure 8-2: The World Market for Urinary Bladder Disorders for Women,
Revenues by Disease Type 2006-2013
• Figure 8-3: The World Market for Urinary Bladder Disorders for Women, Market
Share by Disease Type 2008
• Figure 8-4: The World Market for Urinary Bladder Disorders for Women, Market
Share by Disease Type 2013
• Table 8-5: The World Market for Urinary Bladder Disorders for Women Market
Analysis by Region/Country, 2008
• Figure 8-5: The World Market for Urinary Bladder Disorders for Women Market
Analysis by Region/Country, 2008
• Table 8-6: Select Products in Development for Urinary Disorders 2008
• Table 8-7: The World Market for Urinary Bladder Disorders for Women Revenues
and Market Share by Supplier 2008
• Figure 8-6: The World Market for Urinary Bladder Disorders for Women Market
Share by Leading Supplier 2008
CHAPTER NINE: WORLD MARKET SUMMARY
• Table 9-1: The World Market for Women’s Disorders, Revenues by Product
Segment 2006-2013
• Figure 9-1: The World Market for Women’s Disorders, Revenues by Product
Segment 2006-2013
CHAPTER TEN: CORPORATE PROFILES AND ANALYSIS
13. • Table 10-1: The World Market for Women’s Disorders, Revenues and Market
Share by Supplier 2008
• Figure 10-2: The World Market for Women’s Disorders, Top Ten Suppliers by
Percent, 2008
Available immediately for Online Download at
http://www.marketresearch.com/product/display.asp?productid=2071673
US: 800.298.5699
UK +44.207.256.3920
Int'l: +1.240.747.3093
Fax: 240.747.3004
